ACU-193 is under clinical development by Acumen Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ACU-193’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 26 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ACU-193 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ACU-193 overview

ACU-193 is under development for the treatment of Alzheimer's disease and mild cognitive impairment due to AD. It is a fully-humanized, IgG2 murine monoclonal antibody capable of selective binding to soluble abeta oligomers/ADDLs (amyloid precursor protein). It is administered through the intravenous route as infusion. ADDLs are highly ordered aggregates of amyloid-beta 1-42 peptides. It is developed based on ADDL-Select technology.

Acumen Pharmaceuticals overview

Acumen Pharmaceuticals (Acumen) is a developer of therapeutics and diagnostics for the treatment of Alzheimer’s disease and related neurodegenerative conditions. The company discovers and develops ADDL-Select antibodies that target soluble amyloid-beta oligomers that inhibit nerve function, trigger early memory deficits, initiate nerve cell degeneration and downstream pathological events in Alzheimer’s. Its lead candidate include ACU-193, an anti-ADDL antibody which is in preclinical development stage. Acumen also uses an ultra-high sensitivity assay to measure soluble amyloid-beta oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials.The company owns intellectual property for soluble A-beta oligomers, ADDLs and related therapeutics and diagnostics. Acumen is headquartered in Livermore, California, the US.

Quick View ACU-193 LOA Data

Report Segments
  • Innovator
Drug Name
  • ACU-193
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: Acumen Pharmaceuticals
  • Originator: Acumen BioPharma
Highest Development Stage
  • Phase I


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.